Summary of clinicopathological variables by immune group
| N | IG1 | IG2 | IG3 | P value | |
| N=281 | N=191 | N=44 | |||
| Age, median (range) | 385 | 66.00 (28.00–86.00) | 63.70 (30.20–84.50) | 63.20 (18.80–76.00) | 0.021 |
| Sex, N (%) | 385 | 0.115 | |||
| Male | 166 (83.42%) | 120 (81.63%) | 27 (69.23%) | ||
| Female | 33 (16.58%) | 27 (18.37%) | 12 (30.77%) | ||
| Stage, N (%) | 348 | 0.888 | |||
| Stage I | 10 (5.32%) | 9 (7.26%) | 3 (8.33%) | ||
| Stage II | 33 (17.55%) | 21 (16.94%) | 7 (19.44%) | ||
| Stage III | 108 (57.45%) | 68 (54.84%) | 22 (61.11%) | ||
| Stage IV | 37 (19.68%) | 26 (20.97%) | 4 (11.11%) | ||
| Histology, N (%) | 507 | 0.001 | |||
| Epithelioid | 170 (62.04%) | 140 (73.68%) | 39 (90.70%) | ||
| Biphasic | 84 (30.66%) | 39 (20.53%) | 4 (9.30%) | ||
| Sarcomatoid | 20 (7.30%) | 11 (5.79%) | 0 (0.00%) | ||
| Asbestos exposure, N (%) | 351 | 0.068 | |||
| No | 41 (22.53%) | 42 (31.82%) | 15 (40.54%) | ||
| Possible | 1 (0.55%) | 2 (1.52%) | 1 (2.70%) | ||
| Yes | 140 (76.92%) | 88 (66.67%) | 21 (56.76%) | ||
| Neoadjuvant therapy, N (%) | 325 | 0.11 | |||
| No | 163 (93.68%) | 101 (87.07%) | 30 (85.71%) | ||
| Yes | 11 (6.32%) | 15 (12.93%) | 5 (14.29%) |